The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Mass spectrometry kinetics of monoclonal protein clearance in multiple myeloma
Noemi Puig, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses preliminary findings on the kinetics of monoclonal protein clearance measured by mass spectrometry in patients with multiple myeloma who have achieved complete response. She highlights differences in clearance kinetics between IgG and IgA monoclonal proteins and the potential for persistent mass spectrometry positivity to reflect delayed protein clearance rather than residual disease, while emphasizing the need for longer follow-up and additional samples. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
